Mergers & AcquisitionsBy The Online Investor Staff, updated Sat., Sep. 19, 7:34 AM
|This Slide: #52 of 100|
Slide #52. Mylan N.V. — Aspen Pharmacare Holdings Limited's thrombosis business in Europe
Mylan N.V. (NASDAQ:MYL)
Aspen Pharmacare Holdings Limited's thrombosis business in Europe
Mylan N.V. (NASDAQ: MYL) today announced an agreement to acquire the related intellectual property and commercialization rights of Aspen Pharmacare Holdings Limited's thrombosis business in Europe for EUR 641.9 million, subject to customary closing conditions and European regulatory clearances. The transaction is expected to be immediately accretive to Mylan upon closing and is anticipated to be accretive to VIATRISTM upon the completion of Mylan's previously announced combination with Upjohn that is expected to close in the fourth quarter of 2020.
Mylan is engaged in the global development, licensing, manufacture, marketing and distribution of generic, branded generic, brand-name and over-the-counter (OTC) pharmaceutical products for resale by others and active pharmaceutical ingredients (API) through three reportable segments on a geographic basis, North America, Europe and Rest of World. Co.'s API business is conducted through its subsidiary, Mylan Laboratories Limited, which is included within its Rest of World segment. Among Co.'s branded prescription products are EpiPen® Auto-Injector, Perforomist® Inhalation Solution and Dymista®. Co.'s OTC portfolio includes Cold-EEZE®, MidNite® and Vivarin®, as well as other products.
Mylan SEC Filing Email Alerts Service
Open the MYL Page at The Online Investor »
Buy (2.73 out of 4)
(ranked lower than approx. 76% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite